Skip to main content
LEAP THERAPEUTICS, INC. logo

LEAP THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LPTX ISIN · US52187K2006 LEI · 549300T31SMMJ2DDLI13 US Manufacturing
Filings indexed 584 across all filing types
Latest filing 2023-08-25 Director's Dealing
Country US United States of America
Listing US LPTX

About LEAP THERAPEUTICS, INC.

https://www.leaptx.com/

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics for cancer. Its most advanced clinical candidate, DKN-01 (sirexatamab), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed for patients with esophagogastric, gynecologic, and colorectal cancers. The company's pipeline also includes FL-301, a monoclonal antibody targeting Claudin18.2 for gastric and pancreatic cancer, and FL-501, a preclinical antibody targeting the growth and differentiation factor 15 (GDF-15) protein.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2023-08-25 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-08-25 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-08-25 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-08-25 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 14, 2023, reporting the results of operations and financial condition for the quarter ended June 30, 2023. It includes a press release as an exhibit announcing the financial results. The text explicitly states it is a Current Report (Form 8-K) and not the full quarterly report itself. The document length is 4301 characters, which is relatively short and mainly serves as an announcement of the earnings release rather than containing detailed financial statements or analysis. According to the classification rules, initial announcements of quarterly financial results (key highlights only) are classified as Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2023-08-14 English
10-Q
Interim / Quarterly Report Q2 2023
2023-08-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.